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Objectives: To estimate the incremental cost-utility ratio (ICUR) for the use of a 
continuous infusion pump with integrated monitoring (SAP) compared with the 
application of multiple daily injections (MDI) in adult (> 15 year-old) patients with 
type 1 diabetes mellitus (DM1) in Colombia. MethOds: We designed an annual 
cycle Markov model, with transition probabilities obtained from a systematic review 
of the literature. Outcomes included in the search were ketoacidosis, severe hypogly-
cemia, microvascular complications (retinopathy, nephropathy, neuropathy), quality 
of life (expressed in quality-adjusted life years, QALYs, and obtained from Tufts 
database), as well as mortality. Other features of the model were: discount rate 3.5% 
for costs and QALYs, third party payer perspective (only direct medical costs), and 
a lifespan time horizon (up to 55 years). Threshold used was three times per capita 
gross domestic product (GDP), equivalent to € 17,547. Costs were estimated in 2014 
Colombian pesos (1 euro = 2,660 COP), from base case scenarios (built by expert 
panels) and official tariff manuals. Univariate and probabilistic sensitivity analy-
sis were performed. Results: For the average patient, continuous infusion pump 
has a total expected cost of € 199,296, and generates 16.40 QALYs, while multiple 
daily injections would cost € 104737, and generate 14.48 QALYs (ICER € 49,302 per 
additional QALY gained). Sensitivity analysis shows that the only critical variable 
is the annual cost of continuous infusion pump treatment, which would have to 
be reduced by 40% to reach the cost-utility threshold. cOnclusiOns: Under the 
assumptions of the model, treatment with continuous infusion pumps would not 
be cost-effective for the average adult DM1 patient in Colombia. Further analysis 
would be required, addressed to certain selected subgroups of patients.
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Objectives: To evaluate cost-utility of HAL assisted TURB in comparison to TURB 
with WLC alone in patients with previously diagnosed NIMBC in Poland. MethOds: 
Analysis was performed in 2014, from a public payer’s perspective with a lifetime hori-
zon. “HAL cost-effectiveness model in non-muscle invasive bladder cancer (NIMBC)” 
by Pharmerit Ltd. was adapted to Polish settings. The model consists of two parts: 
a short-term decision tree to assess outcomes of TURB and a Markov cohort model 
developed in order to examine long-term outcomes. Clinical efficacy of HAL was based 
on a systematic review of randomized clinical trials. Data concerning course of disease 
and standard of care in Poland were based on available observational studies, expert 
opinion and guidelines. Difference in utilization of resources between HAL assisted 
TURB and TURB with WLC alone was estimated on the basis of expert survey. Unit 
costs of drugs and medical procedures were based on Ministry of Health (MoH) and 
National Health Fund tariffs. Costs and effects were discounted at rates of 5% and 
3.5%, respectively. The cost-effectiveness threshold was set to 119,577 PLN accord-
ing to MoH requirements. Probabilistic sensitivity analyses (PSA) were conducted 
to assess the probability that HAL is cost-effective in Polish settings. Results: The 
difference in health outcomes between HAL assisted TURB and TURB with WLC alone 
was 0.034 QALY in favor of HAL. HAL assisted TURB was approximately 172 PLN more 
expensive than TURB with WLC alone. Incremental cost per QALY equaled 4,997 PLN. 
PSA indicated that HAL was cost-effective with probability of 95.9% and dominant 
with probability of 44.6%. cOnclusiOns: Use of HAL to assist TURB is cost-effective 
in Poland when compared with TURB with WLC alone.
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Objectives: To assess the cost-effectiveness and to project the clinical ben-
efits of sensor augmented pump (SAP) compared to continuous subcutane-
ous insulin infusion therapy alone (CSII), in type 1 diabetic patients (T1D), in 
Netherlands. MethOds: The Core Diabetes Model was used to project the incidence 
of diabetes-related complications, based on a meta-analysis from Pickup comparing 
SAP vs CSII. In the Pickup meta-analysis, 70% sensor usage in a population with 
baseline HbA1c of 8.0% led to a reduction of -0.42% versus -0.10% HbA1c, for SAP and 
CSII respectively. The simulated population had a mean age of 27 years with a mean 
diabetes duration of 13 years. The quality of life was adjusted for a reduced fear of 
hypoglycaemic event in the SAP arm. A discount rate of 4% and 1.5% for respec-
tively economic and clinical outcomes was applied. Several sensitivity analysis 
were conducted on key parameters. Results: The incremental cost-effectiveness 
ratio (ICER) was 22,335 € per Quality Adjusted Life Year gained (QALY) based on 
a societal perspective. The improvement in discounted QALY was 1.768 years in 
favor of SAP. SAP additional related costs were partially offset by the savings due to 
the reduction in diabetes long-term complications and lower frequency of SMBG. 
Reduction in the incidence (%) and delay of onset of diabetes complications (years) 
were achieved with SAP compared to CSII alone, such as neuropathy (13% 1.3 years), 
first ulcer (5% 1.19 years) and stroke (4% 0.81 years). The acceptability curve showed 
that the likelihood to be cost-effective at a willingness to pay of 80,000 € /QALY 
was 100%. cOnclusiOns: These results indicate that accordingly to commonly 
accepted threshold SAP compared to CSII alone can be considered as very good 
value for money in the Dutch setting. Extensive sensitivity analysis on key drivers 
confirmed the robustness of results.
follow-up this may not always be the most cost-effective alternative. In fact, eco-
nomic evaluations have shown that incremental cost-effectiveness ratios (ICERs) 
of CRT-D may be substantially higher than for comparators. A recent study dem-
onstrated that certain biomarkers may in fact reflect the increased susceptibility 
to SCD in patients with HF and this may further contribute to increase cost-effec-
tiveness of the CRT-D interventions. The objective of this study was to explore the 
cost–effectiveness of a hypothetical perfect biomarker for risk assessment and sub-
sequent treatment decision in implanting CRT-Ds in heart failure patients who com-
ply with the current clinical guidelines and assess the societal value (headroom) of 
such test. MethOds: The study uses a decision analytical model. Results: The use 
of a hypothetical perfect biomarker for implanting CRT-Ds in heart failure patients is 
a cost-effective healthcare intervention. The headroom (societal willingness to pay 
multiplied by incremental quality-adjusted life years) available for the hypothetical 
perfect biomarker ranged from € 1,530 to € 6,120 depending on the willingness to pay 
threshold. cOnclusiOns: The use of a hypothetical perfect biomarker for implant-
ing CRT-D is cost effective. Substantial cost can be saved by a better identification of 
patients with high-risk for SCD and for whom implantation of CRT-Ds reduces risks 
of death. However, further research of risk stratifying biomarkers test accuracy is 
needed to support and strengthen the results of this modeling study.
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Objectives: To investigate the long-term cost-effectiveness of initiating transanal 
irrigation* (TAI) as second-line management in patients with neurogenic bowel 
dysfunction (NBD) who have failed first-line standard bowel care (SBC). MethOds: 
A deterministic Markov decision model was developed to project the lifetime health 
economic outcomes, including quality-adjusted life expectancy (QALE), episodes 
of faecal incontinence (FI), urinary tract infections (UTIs), and stoma surgery when 
using TAI relative to continuing SBC. Patients could transition from TAI to (a) another 
round of first-line SBC, (b) third-line surgeries (sacral nerve stimulator, sacral ante-
rior root stimulator, antegrade continence enema) or (c) stoma as the absorbing 
state. Transition probabilities and QALE estimates were based on real-world data 
collected at three clinics in UK from 2007-2014, in NBD patients due to spinal cord 
injury (SCI), multiple sclerosis, spina bifida, and cauda equina syndrome. Transition 
probabilities for failed SBC patients were collected from 2000-2007 prior to avail-
ability of TAI. Projected life-expectancy was based on published SCI population data. 
One-way sensitivity analyses were applied. Results: The model predicts that a SCI 
patient diagnosed aged 30, with a life expectancy of 37 years using TAI, will experi-
ence a 36.1% reduction in FI, 28.7% reduction in UTIs, a 35.4% reduction in stoma 
surgery and improvement of 0.40 years of QALE, compared with patients continuing 
SBC. Lifetime cost-savings of £41,620 per patient was estimated for TAI versus SBC 
in a SCI patient, primarily due to avoided hospitalizations and stoma surgeries. 
Incremental cost can differ due to altered life-expectancy (and age of diagnosis) in 
the patient cohort. One-way sensitivity analyses indicated that the model was most 
sensitive to variation in utilities on TAI and SBC treatment. cOnclusiOns: TAI is a 
cost-saving treatment strategy reducing risk of stoma surgery and improving QALE 
for NBD patients who have failed SBC. *Peristeen (Coloplast A/S).
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Objectives: To assess the reduction of complications and costs with continu-
ous subcutaneous insulin infusion (CSII) versus multiple daily injections (MDI) in 
uncontrolled type 2 diabetic patients (T2D) in the UK. MethOds: The incidence of 
diabetes-related complications was calculated based on the Core Diabetes Model. 
The population characteristics, the reduction of HbA1c, and insulin dose were based 
on the Opt2mise study (Reznik et al., Lancet 2014) (mean age 56 years (SD 9.6); mean 
diabetes duration 15 years (SD 0.75)). For a baseline HbA1c of 9.0%, the reduction in 
HbA1c was -1.1 % versus -0.4%, respectively, for CSII vs MDI. Costs were UK-specific 
and expressed in £2014. Results: The diabetes-related complications were reduced 
with CSII. At 5 years, the incidence reduction in complications associated with eye dis-
eases, renal diseases, ulcer/amputation and cardiovascular diseases were -24%, -26%, 
-19% and -10%, respectively, in favour of CSII. This equates to a cost reduction of 12% 
over 5 years per patient. End stage renal disease was delayed by 1 year, neuropathy by 
1.08 years and amputation by 0.87 year, myocardial infarction and stroke by 0.81 and 
0.71 year respectively. Insulin dose was reduced for patients on CSII from 122.1 IU to 
96.5 IU per day with a cost saving of £2,169 per patient over 5 years. cOnclusiOns: 
Improvements in HbA1c with a decrease in overall insulin requirements observed 
with CSII versus MDI, may offer important reductions in diabetes-related complica-
tions and associated costs in a UK setting for uncontrolled T2DM patients.
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